Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
European Journal of Neurology|August 4, 2025
Improvement in Patient-Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PROHenry J Kaminski, Carlo Antozzi, Ali A Habib, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|November 20, 2009
Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerabilityGiuseppe Lauria, Angela Campanella, Graziella Filippini, et al.
European Journal of Neurology|January 2, 2024
Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference centerRita Frangiamore, Elena Rinaldi, Fiammetta Vanoli, et al.
Behavioural Neurology|January 22, 2025
Anxiety, Depression, and Expanded Disability Status Scale Independently Predict the Perception of Disability in Persons With Multiple Sclerosis: A Cross-Sectional StudyChiara Curatoli, Alessia Marcassoli, Filippo Barbadoro, et al.
Journal of Neuroimmunology|June 18, 2013
Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorptionRosetta Pedotti, Silvia Musio, Stefano Scabeni, et al.
Brain : a Journal of Neurology|May 31, 2007
Novel mutations of ND genes in complex I deficiency associated with mitochondrial encephalopathyEdoardo Malfatti, Marianna Bugiani, Federica Invernizzi, et al.
Journal of Neurology|October 11, 2025
Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover studyVera Bril, Carlo Antozzi, Tomasz Berkowicz, et al.
Pharmacogenetics and Genomics|December 7, 2016
A novel ABCC6 haplotype is associated with azathioprine drug response in myasthenia gravisLara Colleoni, Barbara Galbardi, Claudia Barzago, et al.
European Journal of Neurology|May 20, 2026
Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 StudyTuan Vu, Said R Beydoun, Richard J Nowak, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 31, 2025
Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis: A New Mechanism of Action Beyond IgG ReductionMaria Cristina Tarasco, Elena Rinaldi, Rita Frangiamore, et al.
Pageof 9